Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentration...
Saved in:
| Published in: | Antimicrobial agents and chemotherapy Vol. 64; no. 9 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
20.08.2020
|
| Subjects: | |
| ISSN: | 1098-6596, 1098-6596 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentrations and the levels of the acute-phase inflammation marker C-reactive protein (CRP). LPV plasma concentrations in 92 patients hospitalized at our institution were prospectively collected. Lopinavir-ritonavir was administered every 12 hours, 800/200 mg on day 1 and 400/100 mg on day 2 until day 5 or 7. HCQ was given at 800 mg, followed by 400 mg after 6, 24, and 48 h. Hematological, liver, kidney, and inflammation laboratory values were analyzed on the day of drug level determination. The median age of study participants was 59 (range, 24 to 85) years, and 71% were male. The median durations from symptom onset to hospitalization and treatment initiation were 7 days (interquartile range [IQR], 4 to 10) and 8 days (IQR, 5 to 10), respectively. The median LPV trough concentration on day 3 of treatment was 26.5 μg/ml (IQR, 18.9 to 31.5). LPV plasma concentrations positively correlated with CRP values (
= 0.37,
< 0.001) and were significantly lower when tocilizumab was preadministered. No correlation was found between HCQ concentrations and CRP values. High LPV plasma concentrations were observed in COVID-19 patients. The ratio of calculated unbound drug fraction to published SARS-CoV-2 50% effective concentrations (EC
) indicated insufficient LPV concentrations in the lung. CRP values significantly correlated with LPV but not HCQ plasma concentrations, implying inhibition of cytochrome P450 3A4 (CYP3A4) metabolism by inflammation. |
|---|---|
| AbstractList | Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentrations and the levels of the acute-phase inflammation marker C-reactive protein (CRP). LPV plasma concentrations in 92 patients hospitalized at our institution were prospectively collected. Lopinavir-ritonavir was administered every 12 hours, 800/200 mg on day 1 and 400/100 mg on day 2 until day 5 or 7. HCQ was given at 800 mg, followed by 400 mg after 6, 24, and 48 h. Hematological, liver, kidney, and inflammation laboratory values were analyzed on the day of drug level determination. The median age of study participants was 59 (range, 24 to 85) years, and 71% were male. The median durations from symptom onset to hospitalization and treatment initiation were 7 days (interquartile range [IQR], 4 to 10) and 8 days (IQR, 5 to 10), respectively. The median LPV trough concentration on day 3 of treatment was 26.5 μg/ml (IQR, 18.9 to 31.5). LPV plasma concentrations positively correlated with CRP values (r = 0.37, P < 0.001) and were significantly lower when tocilizumab was preadministered. No correlation was found between HCQ concentrations and CRP values. High LPV plasma concentrations were observed in COVID-19 patients. The ratio of calculated unbound drug fraction to published SARS-CoV-2 50% effective concentrations (EC50) indicated insufficient LPV concentrations in the lung. CRP values significantly correlated with LPV but not HCQ plasma concentrations, implying inhibition of cytochrome P450 3A4 (CYP3A4) metabolism by inflammation.Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentrations and the levels of the acute-phase inflammation marker C-reactive protein (CRP). LPV plasma concentrations in 92 patients hospitalized at our institution were prospectively collected. Lopinavir-ritonavir was administered every 12 hours, 800/200 mg on day 1 and 400/100 mg on day 2 until day 5 or 7. HCQ was given at 800 mg, followed by 400 mg after 6, 24, and 48 h. Hematological, liver, kidney, and inflammation laboratory values were analyzed on the day of drug level determination. The median age of study participants was 59 (range, 24 to 85) years, and 71% were male. The median durations from symptom onset to hospitalization and treatment initiation were 7 days (interquartile range [IQR], 4 to 10) and 8 days (IQR, 5 to 10), respectively. The median LPV trough concentration on day 3 of treatment was 26.5 μg/ml (IQR, 18.9 to 31.5). LPV plasma concentrations positively correlated with CRP values (r = 0.37, P < 0.001) and were significantly lower when tocilizumab was preadministered. No correlation was found between HCQ concentrations and CRP values. High LPV plasma concentrations were observed in COVID-19 patients. The ratio of calculated unbound drug fraction to published SARS-CoV-2 50% effective concentrations (EC50) indicated insufficient LPV concentrations in the lung. CRP values significantly correlated with LPV but not HCQ plasma concentrations, implying inhibition of cytochrome P450 3A4 (CYP3A4) metabolism by inflammation. Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentrations and the levels of the acute-phase inflammation marker C-reactive protein (CRP). LPV plasma concentrations in 92 patients hospitalized at our institution were prospectively collected. Lopinavir-ritonavir was administered every 12 hours, 800/200 mg on day 1 and 400/100 mg on day 2 until day 5 or 7. HCQ was given at 800 mg, followed by 400 mg after 6, 24, and 48 h. Hematological, liver, kidney, and inflammation laboratory values were analyzed on the day of drug level determination. The median age of study participants was 59 (range, 24 to 85) years, and 71% were male. The median durations from symptom onset to hospitalization and treatment initiation were 7 days (interquartile range [IQR], 4 to 10) and 8 days (IQR, 5 to 10), respectively. The median LPV trough concentration on day 3 of treatment was 26.5 μg/ml (IQR, 18.9 to 31.5). LPV plasma concentrations positively correlated with CRP values ( = 0.37, < 0.001) and were significantly lower when tocilizumab was preadministered. No correlation was found between HCQ concentrations and CRP values. High LPV plasma concentrations were observed in COVID-19 patients. The ratio of calculated unbound drug fraction to published SARS-CoV-2 50% effective concentrations (EC ) indicated insufficient LPV concentrations in the lung. CRP values significantly correlated with LPV but not HCQ plasma concentrations, implying inhibition of cytochrome P450 3A4 (CYP3A4) metabolism by inflammation. |
| Author | Mueller, Daniel Battegay, Manuel Gebhard, Caroline E Weisser, Maja Marzolini, Catia Franzeck, Fabian Sendi, Parham Osthoff, Michael Hirsch, Hans H Hollinger, Alexa Egli, Adrian Baettig, Veronika Khanna, Nina Stader, Felix Tschudin-Sutter, Sarah Bassetti, Stefano Geenen, Julia Stoeckle, Marcel |
| Author_xml | – sequence: 1 givenname: Catia orcidid: 0000-0002-2312-7050 surname: Marzolini fullname: Marzolini, Catia email: catia.marzolini@usb.ch, parham.sendi@usb.ch organization: Division of Infectious Diseases & Hospital Hygiene, University Hospital Basel and University of Basel, Basel, Switzerland catia.marzolini@usb.ch parham.sendi@usb.ch – sequence: 2 givenname: Felix surname: Stader fullname: Stader, Felix organization: Division of Infectious Diseases & Hospital Hygiene, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 3 givenname: Marcel surname: Stoeckle fullname: Stoeckle, Marcel organization: Division of Infectious Diseases & Hospital Hygiene, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 4 givenname: Fabian surname: Franzeck fullname: Franzeck, Fabian organization: Research and Analysis Services, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 5 givenname: Adrian surname: Egli fullname: Egli, Adrian organization: Applied Microbiology Research, Department of Biomedicine, University of Basel, Basel, Switzerland – sequence: 6 givenname: Stefano surname: Bassetti fullname: Bassetti, Stefano organization: Division of Internal Medicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 7 givenname: Alexa surname: Hollinger fullname: Hollinger, Alexa organization: Intensive Care Unit, University Hospital Basel, Basel, Switzerland – sequence: 8 givenname: Michael surname: Osthoff fullname: Osthoff, Michael organization: Division of Internal Medicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 9 givenname: Maja surname: Weisser fullname: Weisser, Maja organization: Division of Infectious Diseases & Hospital Hygiene, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 10 givenname: Caroline E surname: Gebhard fullname: Gebhard, Caroline E organization: Intensive Care Unit, University Hospital Basel, Basel, Switzerland – sequence: 11 givenname: Veronika surname: Baettig fullname: Baettig, Veronika organization: Division of Infectious Diseases & Hospital Hygiene, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 12 givenname: Julia surname: Geenen fullname: Geenen, Julia organization: Division of Internal Medicine and Department of Clinical Research, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 13 givenname: Nina surname: Khanna fullname: Khanna, Nina organization: Division of Infectious Diseases & Hospital Hygiene, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 14 givenname: Sarah surname: Tschudin-Sutter fullname: Tschudin-Sutter, Sarah organization: Division of Infectious Diseases & Hospital Hygiene, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 15 givenname: Daniel surname: Mueller fullname: Mueller, Daniel organization: Institute of Clinical Chemistry, University Hospital Zurich, Zurich, Switzerland – sequence: 16 givenname: Hans H surname: Hirsch fullname: Hirsch, Hans H organization: Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland – sequence: 17 givenname: Manuel surname: Battegay fullname: Battegay, Manuel organization: Division of Infectious Diseases & Hospital Hygiene, University Hospital Basel and University of Basel, Basel, Switzerland – sequence: 18 givenname: Parham surname: Sendi fullname: Sendi, Parham email: catia.marzolini@usb.ch, parham.sendi@usb.ch organization: Institute for Infectious Diseases, University of Bern, Bern, Switzerland |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32641296$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUN9LwzAYDDJxP_TNZ8mjL51J2qbtYynTDQbKpr6Wb-kXrLRJbTKx_70VJ3gvdwfHcdycTIw1SMg1Z0vORXqX58WScZ4kgWBnZMZZlgYyzuTkn56SuXPvjLHRsAsyDYWMuMjkjHQrrVF5ajXdD85jWyu6MbqBtgVv-4Hu0HXWOKTe0n2-2weFfQ0EtYZubVcb-Kx7Cqai66Hq7deg3hrb249jbZA-NeBaoIU1Co3vwddj0SU519A4vDrxgrzcr56LdbB9fNgU-TaAKI18gJnkWkuVVqgkMIAoSxAPijGdhmGUVckIEeokQVAy5HGcRlCBSEGGyYGBWJDb397uZw46X7a1U9g0YNAeXSkiIRhnMeNj9OYUPR5arMqur1voh_LvJfENwjlrmg |
| CitedBy_id | crossref_primary_10_1002_cpt_2412 crossref_primary_10_1111_bcp_15013 crossref_primary_10_1111_bcp_14684 crossref_primary_10_1002_cpt_2432 crossref_primary_10_1007_s40264_020_01025_z crossref_primary_10_1097_FTD_0000000000000899 crossref_primary_10_1007_s13318_020_00668_8 crossref_primary_10_1016_j_transproceed_2021_01_002 crossref_primary_10_1002_cpt_2814 crossref_primary_10_1111_bcp_14524 crossref_primary_10_1186_s40360_023_00687_6 crossref_primary_10_3390_biomedicines10112686 crossref_primary_10_1016_S0140_6736_20_32013_4 crossref_primary_10_1124_dmd_122_000934 crossref_primary_10_1186_s13054_024_05150_4 crossref_primary_10_1016_j_ijid_2022_12_028 crossref_primary_10_1007_s00134_021_06448_5 crossref_primary_10_1093_jac_dkab412 crossref_primary_10_1016_j_ijcard_2020_10_028 crossref_primary_10_1016_j_cmi_2021_05_020 crossref_primary_10_1007_s40199_023_00484_w crossref_primary_10_3389_fphar_2021_733935 crossref_primary_10_3389_fphar_2021_704767 crossref_primary_10_1002_cpt_2402 crossref_primary_10_1002_psp4_12718 crossref_primary_10_1016_j_chom_2020_11_003 crossref_primary_10_1038_s41392_025_02220_z crossref_primary_10_1159_000512141 crossref_primary_10_1002_ijfe_2586 crossref_primary_10_3390_microorganisms12081696 crossref_primary_10_1080_17425255_2023_2228680 crossref_primary_10_1016_j_therap_2024_12_012 crossref_primary_10_1186_s43094_021_00259_7 crossref_primary_10_1080_07391102_2021_1922095 crossref_primary_10_1124_dmd_122_000926 crossref_primary_10_3390_pathogens14010020 crossref_primary_10_1002_cpt_2196 crossref_primary_10_1016_j_ejps_2025_107003 |
| ContentType | Journal Article |
| Copyright | Copyright © 2020 American Society for Microbiology. |
| Copyright_xml | – notice: Copyright © 2020 American Society for Microbiology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1128/AAC.01177-20 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Biology Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1098-6596 |
| ExternalDocumentID | 32641296 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GroupedDBID | --- .55 0R~ 23M 2WC 39C 4.4 53G 5GY 5RE 5VS 6J9 ACGFO ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW CGR CS3 CUY CVF DIK E3Z EBS ECM EIF F5P FRP GX1 H13 HH5 HYE HZ~ H~9 K-O KQ8 L7B LSO NPM O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UHB W2D W8F WH7 WOQ X7M 7X8 AAGFI |
| ID | FETCH-LOGICAL-a484t-e961ff6c8dec6a0aa497eebc00f83349d777723f77eac6315584ada28a637b0a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 52 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000566461500023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1098-6596 |
| IngestDate | Thu Oct 02 06:22:33 EDT 2025 Thu Jan 02 22:59:20 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Keywords | COVID-19 hydroxychloroquine inflammation lopinavir-ritonavir levels |
| Language | English |
| License | Copyright © 2020 American Society for Microbiology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a484t-e961ff6c8dec6a0aa497eebc00f83349d777723f77eac6315584ada28a637b0a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-2312-7050 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7449226 |
| PMID | 32641296 |
| PQID | 2422010501 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2422010501 pubmed_primary_32641296 |
| PublicationCentury | 2000 |
| PublicationDate | 20200820 |
| PublicationDateYYYYMMDD | 2020-08-20 |
| PublicationDate_xml | – month: 8 year: 2020 text: 20200820 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Antimicrobial agents and chemotherapy |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2020 |
| SSID | ssj0006590 |
| Score | 2.5337172 |
| Snippet | Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| SubjectTerms | Adult Aged Aged, 80 and over Antibodies, Monoclonal, Humanized - therapeutic use Antiviral Agents - blood Antiviral Agents - pharmacokinetics Antiviral Agents - pharmacology Betacoronavirus - drug effects Betacoronavirus - immunology Betacoronavirus - pathogenicity Biomarkers - blood C-Reactive Protein - metabolism Coronavirus Infections - drug therapy Coronavirus Infections - immunology Coronavirus Infections - mortality Coronavirus Infections - virology COVID-19 Cytokine Release Syndrome - drug therapy Cytokine Release Syndrome - immunology Cytokine Release Syndrome - mortality Cytokine Release Syndrome - virology Drug Administration Schedule Drug Combinations Female Hospitals, University Humans Hydroxychloroquine - blood Hydroxychloroquine - pharmacokinetics Hydroxychloroquine - pharmacology Length of Stay - statistics & numerical data Lopinavir - blood Lopinavir - pharmacokinetics Lopinavir - pharmacology Male Middle Aged Pandemics Pneumonia, Viral - drug therapy Pneumonia, Viral - immunology Pneumonia, Viral - mortality Pneumonia, Viral - virology Retrospective Studies Ritonavir - blood Ritonavir - pharmacokinetics Ritonavir - pharmacology SARS-CoV-2 Severity of Illness Index Survival Analysis |
| Title | Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/32641296 https://www.proquest.com/docview/2422010501 |
| Volume | 64 |
| WOSCitedRecordID | wos000566461500023&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3da9swED-2Zit92Ue2tuk-uMHoU7XalqKPpxHCSgdtMG1X8hZkWaKB1k7rtJD_vpLlkKfBYH4QfjGWfeefftbd_Q7gu6IpNZ4HEWOHlLAiY6RIw-CNPdTUSdfWVl2ficlETqcq7zbcmi6tco2JLVCXtQl75Md-KQmB22GS_lzck9A1KkRXuxYaL6Hn76mCV4vpRi2cD1VUI1CS-HO-TnzP5PFoNP4R5NAEyZK_k8t2kTl5-7_TewdvOnqJo-gP7-GFrfrwOjacXPVh-7wLpffhMI-i1asjvNrUYDVHeIj5Rs569QEWUeAYa4dR3nxu8HflvCfdtRF6vIhpthaXNV6OLi7JuL4mGdYVnoVqLP00f0BdlXi6KkPOjLm5rcOz-Vlg7rn7ncZxqJ2sOgHf5iP8Ofl1NT4lXZ8GoplkS2IVT53jRpbWcJ1ozZSwtjBJ4iSlTJXCHxl1QniU59QzGMl0qTOpORVForNd2Krqyu4DlsoIyalOCuWYs1Jbp5zRBU-tE4USA_i2fv0z_x2E4IaubP3YzDYGGMBetOFsEQU7Zp6iMs9r-ME_XP0JdrLwS50EAPkMPedRwH6BV-ZpOW8evrYO5sdJfv4MEZncGA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+Systemic+Inflammatory+Response+to+SARS-CoV-2+on+Lopinavir+and+Hydroxychloroquine+Plasma+Concentrations&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=Marzolini%2C+Catia&rft.au=Stader%2C+Felix&rft.au=Stoeckle%2C+Marcel&rft.au=Franzeck%2C+Fabian&rft.date=2020-08-20&rft.issn=1098-6596&rft.eissn=1098-6596&rft.volume=64&rft.issue=9&rft_id=info:doi/10.1128%2FAAC.01177-20&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1098-6596&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1098-6596&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1098-6596&client=summon |